House · HR 747 · 119th Congress
Stop Chinese Fentanyl Act of 2025
Sign in to cast a dissent vote.
Summary
This bill lets the U.S. punish Chinese companies and government officials linked to fentanyl trafficking. It expands who can be labeled an opioid trafficker and requires the President to weigh costs and benefits before issuing trade rules during a drug emergency. American consumers and businesses are affected through trade and drug supply policies.
In Favor
Fentanyl from Chinese suppliers has killed tens of thousands of Americans each year. This bill gives the government new tools to punish Chinese companies and officials who look the other way while fentanyl reaches U.S. streets. Holding those enablers responsible could slow the flow of deadly drugs into American communities.
Against
Sanctioning Chinese companies could disrupt legal trade in chemicals that American manufacturers also depend on. The bill makes it harder for the President to act quickly during a drug emergency by requiring cost-benefit reviews before issuing trade rules. These added steps could slow the government's response when fast action matters most.
Additional Considerations
Purpose & Problem
Is the problem real and worth federal action?
The bill targets Chinese companies and officials involved in making or selling synthetic opioids and the chemicals used to create them. It updates existing law to let the government apply financial penalties to those found aiding fentanyl trafficking.
Scope & Related Provisions
Does it stay focused, or carry unrelated add-ons?
Most parts of the bill focus on opioid sanctions and related reporting duties. It also adds new steps the President must take before setting rules during any national emergency tied to international drug trafficking, which goes beyond fentanyl alone.
Who Is Affected
Who benefits, and who bears the cost?
Chinese companies and government officials linked to opioid production or sales face potential financial penalties. Federal agencies gain new reporting and review duties, and the President must follow added steps before issuing rules during a drug-related national emergency.
Cost & Funding
Is it affordable and responsibly funded?
The bill does not authorize or appropriate a specific dollar amount. It shifts costs onto the executive branch to conduct annual reviews, evaluate costs and benefits before issuing rules, and report findings to Congress each year through 2029.
Risks & Implementation
What could go wrong in practice?
The bill requires the President to identify specific Chinese officials and companies as traffickers, which depends on collecting reliable evidence from abroad. Agencies must also complete cost-benefit reviews before acting during a declared emergency, which could slow the rule-making process.
For the actual bill text, see congress.gov.
AI-generated · Published 6/5/2026